Scleroderma Drug In Development PDF Print E-mail
Friday, 16 October 2009 10:57
According to The Commercial Appeal, arGentis Pharmaceutical has partnered with Shattuck Hammond Partners, the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.

The money will help continue a three-year effort by arGentis to shepherd a treatment for Scleroderma, an autoimmune disease that affects blood vessels and connective tissue. Ted Townsend, the company's vice president of business development, said the treatment could be on the market as early as 2013.

The company has just finished reviewing the treatment's previous clinical trial. The next trial will be the drug's last before it heads to the Food and Drug Administration for market approval. To help that process along, arGentis has assembled a "dream team" to serve on its scientific advisory board.

For example, new board member Maureen D. Mayes wrote "The Scleroderma Book" in 1999. University of California Los Angeles professor Daniel Furst, Georgetown School of Medicine professor Virginia D. Steen and UCLA biostatistics professor Weng Kee Wong also joined the arGentis scientific advisory board.

"These physicians understand this disease process better than anyone in the world," said Townsend. "Their participation in the trial shows the validity of our therapy and will hopefully reinforce our credibility to regulatory authorities."

However, Charles Spaulding, vice president of communications with the Scleroderma Research Foundation, said the disease largely flies under national research radar.

"There's not enough researchers looking at the disease and not enough money being spent on Scleroderma research," Spaulding said.

ArGentis' Scleroderma treatment received "orphan status" in the United States and in the European Union. The designation gives the company market exclusivity for seven years here and 10 years in Europe.

Townsend said the treatment could be a $1 billion annual opportunity in the U.S. and Europe.

The company also has license agreements in hand for about 50 markets globally.

To view the full article, click here.
 
More articles :

» Four More Tips For Coping With Your Scleroderma

Hosted by Jennifer Romero, jenniferforhealing is an excellent blog which seeks to spread awareness and provide support and hope for those who are suffering from Scleroderma and Lupus. In a recent post on Coping with Autoimmune Disease, Jennifer...

» Godrick Weekes

I am thirty seven years old and I have for the past four years. For me, it has been a roller coaster ride with this condition and its symptoms. In the beginning, I first noticed that my fingers were always swollen on mornings, I could not bend them...

» Unite Against Scleroderma

On May 1st 2011, the would be holding its first annual "Unite Against Scleroderma" Walk around the Queen's Park Savannah, Port Of Spain. It is our aim to help raise awareness of this rare autoimmune disease and the funding needed to aid those who...

» Scientists Identify New Genetic Region Associated with Scleroderma

New research supported, in part, by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has identified a new genetic link to systemic sclerosis (also known as systemic scleroderma) and confirmed three previously...

» Beware of Skin Signs of Illness and Disease

While moisturizers and make-up, facial peels and Botox can make our skin look beautiful and young, sometimes the external skin discolorations, blemishes, blotches or other unsightly marks we seek to remove are actually signs of an underlying...

» Novel Pharmaceutical Treatment for Scleroderma Discovered

A novel pharmaceutical treatment for scleroderma, comprising the administration of miR-29, has been discovered by Steffen Gay, Oliver Distler and Britta Maurer of the Department of Rheumatology at Zurich University. Scleroderma is a chronic...